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Abstract 
 
 Among the 20 amino acids incorporated into a polypeptide chain during protein 
synthesis, arginine (Arg; R) is the one with the highest relative mutability. In genetic diseases, 
almost 15% of missense mutations occur in Arg residues and more than half of these missense 
mutations are Arg to cysteine (Cys; C) substitutions. The Arg residue is more prone to 
mutations due to the fact that this residue can be coded by six different codons, four of them 
containing CpG dinucleotides, a preferential site for cytosine methylation with further 
spontaneous deamination to thymine. 
The effect of the aminothiol compounds cysteamine (CySH) and 
mercaptoethylguanidine (MEG) in the specific rescue of R to C (R>C) mutations have 
already been studied in our group through the characterization of the most common variant 
(p.R336C) found in cystathionine -synthase (CBS) deficiency. It was postulated that those 
compounds would bind to the mutant residue C, forming a structure resembling the wild-type 
(WT) residue R, and thus restoring the enzyme activity. 
Cystathionine--synthase is a cytoplasmatic homotetrameric enzyme. It catalyses the 
condensation of the amino acids L-Homocysteine (L-Hcy) and L-Serine (L-Ser) to form L-
Cystathionine (L-Cth). Each subunit (63 kDa) binds to the cofactors pyridoxal 5'-phosphate 
(PLP) and heme and comprises a N-terminal heme-binding domain, a catalytic core domain 
which binds PLP, and a C-terminal regulatory domain. 
The CBS protein contains 28 Arg residues, localized all over its sequence. In order to 
understand if the rescue of the activity of R>C CBS variants by aminothiol compounds, such 
as CySH and MEG, depends on the localization of the affected residue, six residues 
presenting different accessible surface area (ASA) values and domain localization were 
selected for mutagenesis, namely the R18, R121, R164, R336, R369 and R491 residues. 
Additionally, a control variant corresponding to an Arg residue to histidine (His; H) 
substitution (R>H) was also studied. 
The CBS proteins (WT and variants) were produced in a prokaryotic expression 
system and further purified by affinity chromatography. To evaluate the impact of aminothiol 
compounds on the structure and function of CBS R>C variants, the purified recombinant 
proteins were characterized in the absence and presence of these compounds in respect to 
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their thermostability by differential scanning fluorimetry (DSF),  and to their conformational 
flexibility by susceptibility to limited proteolysis. The enzyme activity and the quantitative 
assessment of free Cys residues were also evaluated. 
The obtained data strongly suggest that MEG, but not CySH, is able to increase the 
resistance to proteolysis of the majority of the studied R>C variants. However, this did not 
result in a higher enzyme activity for all of them. Since the observed effect was independent 
from ASA and domain localization, we anticipate that rescuing of R>C variants by 
aminothiols will be residue-specific and should always be investigated in a case-by-case 
basis. 
 
 
Key words: Cystathionine β-synthase; Classical Homocystinuria; Conformational 
Diseases; Missense mutation; Aminothiol compounds; Accessible surface area; Protein 
rescue; Enzyme activity modulation; Cysteamine; Mercaptoethylguanidine. 
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Resumo 
 
Entre os 20 aminoácidos incorporados numa cadeia polipeptídica durante a síntese 
proteica, a arginina (Arg; R) é o aminoácido com maior mutabilidade relativa. Nas doenças 
genéticas, quase 15% das mutações missense são substituições de arginina para cisteína (Cys; 
C). O resíduo Arg é altamente susceptível a mutagénese devido ao facto de este aminoácido 
poder ser codificado por seis codões diferentes, contendo quatro deles dinucleótidos CpG, 
um local preferencial para a metilação de citosina com posterior desaminação espontânea 
para timina. 
 O efeito dos compostos aminotiol cisteamina (CySH) e mercaptoetilguanidina 
(MEG) na recuperação específica de mutações R para C (R>C) foi já estudado no nosso 
grupo através da caracterização da variante mais comum (p.R336C) da deficiência na enzima 
cistationina β-sintase (CBS). Foi então postulado que estes compostos ligar-se-iam ao resíduo 
Cys mutante, formando uma estrutura semelhante ao resíduo Arg selvagem, restaurando 
assim a actividade enzimática. 
 A proteína CBS é uma enzima homotetramérica citoplasmática. Cada uma das suas 
subunidades (63 KDa) liga-se aos cofatores piridoxal 5'-fosfato (PLP) e heme. Esta enzima 
catalisa a condensação dos aminoácidos L-homocisteína (L-Hcy) e L-serina (L-Ser) para 
formar L-cistationina (L-Cth). Cada monómero da CBS contém três domínios: um domínio 
N-terminal de ligação ao heme, que inclui os primeiros 70 aminoácidos; um domínio 
catalítico, contendo os 340 aminoácidos centrais; e um domínio regulador C-terminal com 
140 resíduos. 
A CBS contém, na sua sequência primária, 28 resíduos de Arg igualmente 
distribuídos pelos diferentes domínios. De modo a compreender se a recuperação da atividade 
das variantes R>C da CBS, por compostos aminotiol como CySH e MEG, depende da 
localização do resíduo afetado, foram selecionados para mutagénese seis resíduos com 
valores de área de superfície acessível (ASA) e diferentes localizações, nomeadamente os 
resíduos R18, R121, R164, R336, R369 e R491. De entre estes, os resíduos R18 e R491 são 
resíduos expostos ao solvente e estão localizados no domínio N-terminal e C-terminal, 
respetivamente. O resíduo R121 apresenta um ASA de apenas 6% e localiza-se no domínio 
catalítico. Os resíduos R164, R336 e R369 são representativos de resíduos parcialmente 
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acessíveis ao solvente, localizando-se na sua totalidade no domínio catalítico. 
Adicionalmente, foi estudada, como controlo, uma substituição equivalente de Arg para 
Histidina (His; H) (R>H). 
As proteínas CBS, selvagem (WT) e variantes, foram produzidas num sistema de 
expressão procariótico e purificadas por cromatografia de afinidade. Para avaliar o impacto 
dos compostos aminotiol na estrutura e função das mutações R>C da CBS, estas variantes 
foram caracterizadas na ausência e presença destes compostos relativamente à sua 
termostabilidade por fluorimetria de varrimento diferencial (DSF), e à sua suscetibilidade à 
proteólise limitada. A atividade enzimática e a aferição quantitativa dos resíduos de Cys 
livres foram também avaliadas. 
Os dados obtidos sugerem que o MEG, mas não a CySH, tem capacidade para 
modular a flexibilidade conformacional (maior resistência à proteólise limitada) das variantes 
e de aumentar a atividade das variantes R>C da CBS. Uma vez que o efeito observado é 
independente do ASA e da localização do resíduo, antecipamos que a recuperação das 
variantes R>C por compostos aminotiol possa ser alargada a outras proteínas com mutações 
R>C, devendo no entanto este efeito sempre ser avaliado especificamente para cada variante. 
 
 
Palavras-chave: Cistationina β-sintase; Homocistinúria Clássica; Doenças 
Conformacionais; Mutação missense; Compostos aminotiol; Área de superfície acessível; 
Recuperação proteica; Modulação da actividade enzimática; Cisteamina; 
Mercaptoetilguanidina. 
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1.1. Conformational Diseases 
Half of all sequence alterations in genetic diseases are missense mutations leading to 
single amino acid substitutions. These can affect not only the activity but also the structure, 
stability and folding of the resulting variant protein, causing its degradation or accumulation 
under the form of aggregates. These diseases are designated conformational disorders and 
can be categorized in loss-of-function or gain-of-function, respectively (Mendre et al., 2010). 
Gain of function disorders usually occur when soluble proteins undergo 
conformational re-arrangements becoming capable of aggregate into β-sheets conformations, 
leading to the production of toxic insoluble complexes known as amyloid deposits, that 
accumulate extracellularly or in the cytoplasm, in the nucleus and at the cell membrane, 
depending on the disease (Guidolin et al., 2012). 
To be biologically active, proteins must present a correct 3D arrangement, determined 
by the amino acid sequence. Proper folding is acquired by interactions established between 
specific residues, which nucleate and trigger the cooperative folding reaction into the final 
topology, corresponding to the most stable structure under physiological conditions. As a 
consequence, the misfolded protein can be targeted for degradation, leading to lower 
intracellular steady-state levels (loss of function disease) (Leandro et al., 2008). 
Specific compounds such as substrates, inhibitors or other ligands are capable of 
binding to misfolded variant proteins and stabilizing them, enabling the acquisition of a near 
native conformation. These molecules known as pharmacological chaperones help the 
defective protein to escape the cell quality control system and therefore, maintain its 
intracellular levels (Mendre et al., 2010). The induced stabilization results essentially from a 
direct effect of small molecular weight (SMW) compounds that correct protein misfolding 
or folding defects, attempting to mimic the function of molecular chaperones (Leandro et al., 
2008).   
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1.2. Classical Homocystinuria 
Hyperhomocysteinaemia, or elevated plasma concentrations of L-homocysteine (L-
Hcy) in blood, can be caused by a range of metabolic disorders, from which the most frequent 
is due to a deficient activity of cystathionine β-synthase (CBS; E.C. 4.2.1.22), an enzyme 
that condensates  L-Hcy and L-serine (L-Ser) into L-cystathionine (L-Cth) (Figure 1). This 
condition is known as classical homocystinuria (Mudd et al., 2001) or CBS deficiency 
(OMIM #236200), and is caused by mutations in the CBS gene. Until present, more than 160 
disease-associated mutations have been identified (http://cbs.lf1.cuni.cz/mutations.php). 
 
 
Figure 1 – Condensation reaction catalyzed by Cystathionine β-Synthase (adapted from Banerjee et 
al, 2005). 
 
 
The CBS gene is localized in chromosome 21, more specifically in the short arm, 22.3 
region (21q22.3) (Münke et al., 1988), and contains 23 exons codifying for a polypeptide of 
551 amino acids (Figure 2). 
 
 
 
Figure 2 – Location in chromosome 21 and structure of the CBS gene. Exons are represented by 
numbered solid boxes. The beginning and the end of the coding region are indicated by the codons 
ATG and TGA, respectively (adapted from Kraus et al., 1998). 
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1.3. Homocysteine and the Methionine Cycle 
Cystathionine β-synthase is an enzyme of the methionine (Met) cycle (Figure 3), 
which plays a key role in sulfur amino acid metabolism in mammalian cells (McKeever et 
al., 1991). The substrate of CBS, L-Hcy, is localized at the intersection point between the 
two remethylation pathways and the transsulfuration pathway (Finkelstein, 1990) (Figure 3). 
About half of the L-Hcy produced in the cell is conserved by remethylation as L-Met 
(Finkelstein et al., 1984). The other half is irreversibly converted by CBS and cystathionine 
γ‐lyase (CGL; E.C. 4.4.1.1) to L-cysteine (L-Cys). Thus, by catalyzing the first step of the 
transsulfuration pathway (Figure 3), CBS is directly involved in the removal of L-Hcy from 
the Met cycle and in the biosynthesis of L-Cys, a precursor of glutathione, the major redox 
regulating metabolite of the cell (Finkelstein et al., 1984). In eukaryotes, the sulfur atom of 
L-Cys is derived from L-Met, while the carbon chain and the amino group originate from L-
Ser (Kraus, 1998).   
The methionine adenosyl transferase (MAT; E.C. 2.5.1.6) initiates the Met cycle by 
converting L-Met into S-adenosylmethionine (SAM) (Kraus, 1998). S-adenosylmethionine 
is the cellular universal donor of methyl groups yielding S-adenosylhomocysteine (SAH) and 
adenosine (Ado) by the activity of various methyl transferases (MT). S-
adenosylhomocysteine is then converted to L-Hcy by S-adenosylhomocysteine hydrolase 
(SAHH; E.C. 3.3.1.1). This enzymatic step is reversible and SAH synthesis is 
thermodynamically favored, unless the products (Ado and L-Hcy) are removed. In one of the 
remethylation pathways L-Hcy is converted to L-Met by methionine synthase (MS), an 
enzyme that requires 5-methyltetrahydrofolate (MTHF) as the methyl donor and 
methylcobalamin (B12) as the coenzyme (Figure 3). The other remethylation pathway of L-
Hcy to L-Met is catalyzed by a second homocysteine methylase, betaine-homocysteine 
methyltransferase (BHMT), and requires betaine has the methyl donor to yield N,N,dimethyl-
glycine.  
In contrast to the ubiquitous Met cycle, transsulfuration has a limited distribution in 
mammalian tissues and all cells lacking this pathway require an exogenous source of L-Cys 
(Finkelstein, 1990). Liver, kidney, small intestine, and pancreas contain both pathways. 
These tissues have a rapid turnover of glutathione, a process that consumes L-Cys (McKeever 
et al., 1991). Interestingly, two of the enzymes of the transsulfuration pathway (CBS and 
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CGL) require as a cofactor the pyridoxal 5’-phosphate (PLP), the active form of vitamin B6 
or pyridoxine.  
The regulation of L-Hcy or L-Met metabolism in mammalian tissues relies on the 
distribution of the substrate between competing reactions at two metabolic sites (Finkelstein, 
1990). The reactions that utilize L-Hcy comprise one of these regulatory sites, as the 
methionine cycle and the transsulfuration pathway both limit the tissue concentration of L-
Hcy (Finkelstein et al., 2000). The other metabolic site relates to the competition for Met 
between protein synthesis and the formation of SAM. 
In fact, the Met cycle is tightly regulated by SAM: an elevated level of this compound 
activates CBS (eliminating L-Hcy in excess) and inhibits MTHFR (reducing the levels of 5-
CH3-THF, the MS substrate). 
 
 
Figure 3 – Methionine cycle. MAT - Methionine adenosyltransferase; SAM - S-
Adenosylmethionine; MT – Methyl transferase; SAH - S-Adenosylhomocysteine; SAHH - S-
Adenosylhomocysteine hydrolase; BHMT - Betaine-homocysteine methyltransferase; MS - 
Methionine synthase; MTHFR - Methylenetetrahydrofolate reductase; SHMT - Serine 
hydroxymethyltransferase; CBS - Cystathionine β-synthase; CGL - Cystathionine γ-lyase; THF - 
Tetrahydrofolate; GSH – Glutathione; GGC - γ-glutamylcysteine; GCL - Glutamate-cysteine ligase; 
GS - GSH synthase (adapted from (Zhang et al., 2013)). 
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1.4. Classical Homocystinuria and Clinical Consequences 
It is known that high concentrations of L-Hcy cause extensive damage to collagen 
and elastic fibers and may lead to a multisystemic disorder involving many organs and 
tissues, notably the cardiovascular and the central nervous systems, the eye, connective 
tissues and muscles (Mudd et al., 1985). Lens dislocation is one of the typical features 
presented by patients with CBS deficiency, and the most common sign leading to diagnosis 
(Mudd et al., 1985; Cruysberg et al., 1996). In these patients, numerous skeletal abnormalities 
resembling the Marfan syndrome may be observed (Mudd et al., 1989), both by clinical and 
X‐ray examinations including scoliosis/kyphosis, dolichostenomelia (long and thin 
extremities), decreased upper/lower segment ratio and arachnodactyly (Skovby et al., 1999). 
Vascular involvement is another peculiar feature of this disease, which can be generally 
characterized as a thrombotic diathesis that may manifest in the venous or arterial system, 
and/or as an accelerated atherosclerosis (Carmel et al., 2001). Mental retardation is also a 
frequent finding in CBS deficient patients (Mudd et al., 1985). 
Two variants of CBS deficiency are recognized: B6-responsive and B6-
nonresponsive (Hu et al., 1993). Vitamin B6-responsive homocystinuria is typically (but not 
always) milder than the nonresponsive variant. In fact, less severe clinical phenotypes are 
observed when comparing untreated B6-responsive and B6-nonresponsive patients, with a 
lower number of B6-responsive patients presenting dislocation of lenses by the age of 10 
years (55% vs. 82%), thromboembolic events by the age of 15 years (12% vs. 27%), spinal 
osteoporosis by the age of 15 years (36% vs. 64%), and mortality by the age of 30 years (4% 
vs. 23%) (Mudd et al., 2001). Quantitative data from 284 patients also showed a median IQ 
of 78 and 56 for the B6 responders and non‐responders, respectively (Mudd et al., 1985).  
 
 
 
1.5. The CBS deficiency as a Conformational Disease 
As previously referred, the majority of disease-causing CBS gene mutations are 
missense mutations leading to single amino acid substitutions in the translated protein. 
Structural characterization of several of these CBS variants demonstrated that the 
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recombinant variants are misfolded proteins, and therefore CBS deficiency is presently 
recognized as a Conformational Disease (Hnízda et al., 2012). 
The rescue of proper folding by chemical/pharmacological chaperones has been 
extensively studied in the last years as a new therapeutic approach to treat Conformational 
Diseases and CBS deficiency has been no exception. In fact, CBS misfolded variants have 
already been a target for folding rescue by the use of different compounds (Kopecká et al., 
2011). 
 
 
 
 1.6. The CBS protein 
Cystathionine -synthase is a cytoplasmatic homotetrameric enzyme, and each 
subunit (63 kDa) binds to two cofactors (PLP and heme) and to two substrates (L- Hcy and 
L-Ser).  
Each monomer of CBS comprises three domains: the heme-binding domain, which 
includes the first 70 N-terminal amino acids; the catalytic core, comprising the central 340 
residues (Ala71–His411) and the C-terminal regulatory domain, with 140 residues (Aitken 
et al., 2005) (Figure 4). Structurally, the monomer is composed of eleven α-helices, seven 
short 310 helices and two β-sheets consisting of four (N-terminal) and six (C-terminal) strands 
(Meier et al., 2001). It has been demonstrated that Lys119 is the PLP binding residue in 
human CBS (Kery et al., 1994). As stated before, CBS is regulated by SAM (Meier et al., 
2001; Pey et al., 2013) which activates the enzyme 2-4 fold (Kožich et al., 1992). This 
allosteric activator binds to the C-terminal regulatory domain and recent data indicate that 
each monomeric subunit binds to 6 mol of SAM (Pey et al., 2013). The presence of heme in 
CBS is surprising and still unclear, as the mechanism of the β-replacement reactions 
catalyzed by the enzyme can occur and be explained solely by PLP mediated catalysis. Heme 
binds to CBS through an N-terminal loop that provides the axial ligands Cys52 and His65. 
The heme resides in a small hydrophobic pocket at the outer end of each dimer, distant from 
the PLP cofactor, which is deeply buried in the active site and accessible only via a narrow 
channel (Meier et al., 2001). The distance of heme from the PLP binding site suggests its 
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non-role in catalysis However, deletion of the heme domain causes loss of redox sensitivity. 
It is, therefore, hypothesized that the heme is a redox sensor (Yamanishi et al., 2006). 
 
 
 
Figure 4 – Domains’ structure and organization of a CBS protein monomer. (A) Schematic 
representation of the structural/functional domains of the full-length CBS with the N-terminal domain 
in cyan, the catalytic core domain in hot pink and the C-terminal regulatory domain in blue. The 
Cys52 and His65 residues, responsible for interaction with heme, are indicated in the N-terminal 
domain; the Lys119 residue, responsible for interaction with PLP, is indicated in the catalytic core 
domain; the CBS1 and CBS2 motifs, responsible for the interaction with SAM, are indicated in the 
C-terminal regulatory domain. (B) Model of the CBS monomer depicted in the same color code as in 
the schematic representation A. The images were obtained using the crystal structure of a truncated 
form of CBS (PDB ID 4L0D) and the UCSF Chimera, version 1.8.1 (build 39231)). 
 
 
 
1.7. The CBS gene mutations 
The incidence of CBS deficiency is thought to be 1:20,000 to 1:60,000 in most 
European countries (Mudd et al., 2001), but may be as low as 1/1,000,000 in some 
populations, like the Japanese (Mudd et al., 1989). On the opposite, an estimated incidence 
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of 1/6,400 has been recently reported from Norway (Refsum et al., 2004) and of 1/3,125 in 
Qatar. The incidence of classical homocystinuria in the Qatari population is at least 5.56 
cases per 10,000 (1/1,800) representing the highest known incidence of this disease in the 
world (Bashir et al., 2015).  
As referred above, more than 160 disease-causing mutations have been identified in 
the CBS gene (http://cbs.lf1.cuni.cz/mutations.php). The mutational spectrum differs 
between countries, and for many mutations it has been determined their vitamin B6 
responsiveness status. Therefore, gene mutation analysis is not only of diagnostic value, but 
it also helps to distinguish between the two clinically relevant B6-responsive and B6-
nonresponsive variants (Mudd et al., 2001). 
Most of the CBS deficient patients carry missense mutations, followed by a few 
nonsense mutations, various deletions, insertions, and splicing mutations. About half of all 
point substitutions in the coding region of the CBS gene are originated from deaminations of 
methylcytosines in CpG dinucleotides (Kraus et al., 1999).  
 
 
1.7.1. R>C mutations in CBS Deficiency 
Among the 20 amino acids incorporated in a polypeptide chain during protein 
synthesis, Arginine (Arg; R) is the one with the highest relative mutability (Khan et al., 2007). 
In fact, in genetic diseases almost 15% of missense mutations occur in Arg residues and 
interestingly more than half of these missense mutations lead to Arg to Cys (R>C) 
substitutions (Steward et al., 2003). The Arg residue is more prone to substitutions as it can 
be coded by six different codons (CGU, CGC, CGA, CGG, AGA, AGG), four of them 
containing CpG dinucleotides (underlined), a preferential site for cytosine methylation with 
further spontaneous deamination to thymine (Vitkup et al., 2003; Coulondre et al., 1978). 
The primary structure of the CBS protein contains 28 Arg residues (Table 1, Figure 
5A), from which residues 18, 121, 336, 369 and 491 present pathogenic R>C substitutions 
(Figure 5B, Table 1), with a total of 93 cases (http://cbs.lf1.cuni.cz/mutations.php). 
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Figure 5 – Human cystathionine -synthase (CBS). (A) Structural representation of the CBS tetramer 
with each monomer represented by a different color and Arg residues depicted in blue. (B) Structural 
representation of a CBS monomer with the Arg residues for which R>C substitutions have been 
described in CBS deficient patients depicted in blue. Images obtained using the crystal structure of a 
truncated form of CBS (PDB ID 4L27) and the UCSF Chimera, version 1.8.1 (build 39231)). 
 
 
In CBS, the Arg residues are equally distributed by the three different domain (≈ 5%), 
being predominantly localized in -helices (≈53.8%). 
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Table 1 – List of CBS Arg residues and respective characteristics 
Residue Domain 
localization1 
ASA2 
(%) 
SS elements3 Functional 
involvement 
R>C disease-causing 
mutation 
18 N - - - Yes 
45 N 50 Random coil - - 
51 N 99 Random coil - - 
58 N 34 Random coil - - 
91 C 32 2 - - 
121 C 6 4 - Yes 
125 C 5 4 - - 
132 C 53 4 - - 
161 C 29 5 - - 
164 C 44 5 - - 
182 C 31 6 - - 
190 C 2 6 - - 
196 C 20 Random coil - - 
209 C 39 7 - - 
224 C 34 Random coil - - 
266 C 17 9 PLP-Heme cross-talk - 
276 C 38 9 - - 
317 C 25 11 - - 
336 C 29 12 - Yes 
369 C 21 11 - Yes 
379 C 6 14 - - 
389 C 62 15 - - 
413 R 59 Random coil - - 
439 R 76 18 - - 
491 R 67 14 - Yes 
498 R 49 21 - - 
527 R - - - - 
548 R 76 22 - - 
1(N) N-terminal; (C) Catalytic; (R) Regulatory. 2(ASA) Accessible surface area. 3(SS) Secondary 
structural elements. 
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Interestingly, among the pathogenic R>C substitutions described in CBS deficient 
patients, the p.R336C variant is highly frequent in Qatar (Bashir et al., 2015). The finding 
that all cases belong to three tribes of the Qatari population clearly points towards a founder 
effect of a CBS gene mutation, in combination with a high incidence of consanguineous 
marriage. In fact, in a study carried out to delineate the genetic and epidemiological aspects 
of homocystinuria in the Qatari population (El-Said et al., 2006), homozygosity for the 
mutation c.1006C>T in exon 11 of the CBS gene, which encodes for the p.R336C variant, 
was found in all but one patient investigated, representing 30 out of 31 independent nuclear 
families. All these 30 families belonged to two single tribes, namely M and K (El-Said et al., 
2006).  
The c.1006C>T mutation, originating the p.R336C variant, was firstly identified in a 
patient of English descent (De Franchis et al., 1999) being subsequently observed in patients 
from Australia (Gaustadnes et al., 2002), Iberian Peninsula (including one homozygous 
Portuguese patient) (Urreizti et al., 2003) and more recently in a Korean patient (Lee et al., 
2005). It is assumed that, most likely, this mutation has recurred independently in different 
populations and therefore, no clear link could be established between this mutation in the 
Qatari population and in the other countries, clearly indicating a strong founder effect, 
making the Qatari population a good study model for the p.R336C variant. 
Clinical observations and enzyme measurements in patients with this variant, as well 
as in vitro expression studies, showed that this mutation has a strong impact on enzyme 
activity and is not associated with vitamin B6-responsiveness (Bashir et al., 2015; Mendes et 
al., 2015). 
The R>C substitution in position 336 of the CBS polypeptide will probably affect the 
stability of the protein by modifying the hydrogen-bonds established by the different amino 
acids, as depicted in figure 6A and 6B, thereby modifying also CBS properties, like solubility 
and activity (Kožich et al., 2010). 
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Figure 6 – Representation of the WT Arg336 (A) and variant Cys336 (B) residues; the H-bonds 
established by Arg336 and Cys336 with neighboring residues are shown. The images were obtained 
using the crystal structure of a truncated form of CBS (PDB ID 4L27) and the UCSF Chimera, version 
1.8.1 (build 39231)). 
 
 
 
1.8. Classical homocystinuria and therapeutic options 
At present, the CBS deficiency is usually treated by administration of large doses of 
vitamin B6 (the PLP precursor) combined with methionine restriction, cysteine 
supplementation, and enhancement of homocysteine remethylation by betaine and folates 
(Kožich et al., 2011). As referred previously, vitamin B6 supplementation may be sufficient 
to treat patients designated as B6-responsive. These patients show a very successful 
 
 
15 
 
improvement in their clinical phenotype when receiving pharmacological doses of B6. It is, 
therefore, recommended that new patients should always be tested for vitamin B6 response. 
As about 50% of CBS deficient patients are nonresponsive to vitamin B6 and the 
management of their diet is quite difficult, especially in late-diagnosed cases, new therapeutic 
options are highly desirable. 
Misassembly and aggregation of CBS variants have been described to contribute 
substantially to the pathogenesis of CBS deficiency. In recent years, chemical and 
pharmacological chaperones have been reported as a therapeutic option to prevent misfolding 
or aberrant trafficking of proteins involved in human conformational diseases (Perlmutter, 
2002), and as such, these compounds have also been investigated for their ability to facilitate 
the proper assembly of several CBS variants (Kopecká et al., 2011). The finding that 
misfolding and decreased activities of some variant proteins may be corrected with the help 
of chemical chaperones further supports the role of misfolding in the pathogenesis of CBS 
deficiency and highlight the relevance of identifying pharmacological chaperones (Singh et 
al., 2007). The proof-of-concept has been already provided, since heme arginate was 
demonstrated to substantially increase the content and rescue the catalytic activity of seven 
CBS variants, namely the p.A114V, p.K102N, p.R125Q, p.R266K and p.R369C 
(Melenovská et al., 2015). 
 
 
1.8.1. The rescue of p.R336C variant by thiol compounds 
It has been shown for two unrelated proteins (ApoE and Factor VIII light chain) that 
the deleterious effect of R>C substitutions could be functionally overcome by the presence 
of cysteamine, an aminothiol compound (Horie et al., 1992; Aly et al., 1992). Recently, 
Mendes and colleagues aimed to study the effect of not only cysteamine (CySH) but also 
mercaptoethylguanidine (MEG), another thiol compound, in the specific rescue of the 
p.R336C variant of CBS (Mendes et al., 2015). Cysteamine is the simplest stable aminothiol 
and a degradation product of Cys (Reid, 1958), while MEG is formed by transguanylation 
when S-(2-aminoethyl)-thiuronium bromide hydrobromide is dissolved in aqueous buffered 
solutions at neutral pH (Schwartz et al., 1960). Cysteamine has shown not only a 
neuroprotective effect, but also the capacity to protect the liver against acetaminophen 
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poisoning via the enhancement of the antioxidant glutathione system (Peterson et al., 1992; 
Prescott et al., 1976; Di Leandro et al., 2008; Lesort et al., 2003; Pillai et al., 2008). MEG is 
a selective inhibitor of inducible nitric oxide synthase (iNOS) and a peroxynitrite scavenger 
(Lohinai et al., 1998). It presents anti-inflammatory properties, including direct inhibition of 
cyclooxygenase (COX) activity, being also a potent scavenging of hydroxyl radicals (Lohinai 
et al., 1998).  
Mendes and colleagues postulated that these thiols would bind to the mutant residue 
Cys, forming a structure resembling the wild-type (WT) residue Arg, thereby restoring 
enzyme activity (Mendes et al., 2013). Interestingly, in all tested conditions the p.R336C 
variant showed an increase in activity. A 6- and 17-fold increase was observed when samples 
were incubated for 7h, at 37°C, with 0.25 mM CySH and 1 mM MEG, respectively. No effect 
was observed for the p.R336H or WT proteins or when Cys was used instead of CySH or 
MEG. Thermal inactivation profiles were also performed and similar results were obtained: 
no changes for the WT, but a clear shift of the T1/2 of p.R336C to values similar to the WT 
in the presence of both CySH and MEG. Taking all together, these data support the 
hypothesis that these compounds specifically rescue the R>C substitution on position 336 of 
the CBS protein (Mendes et al., 2013).  
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Presently, a high number of genetic diseases, and in particular Inherited Metabolic 
Disorders, are classified as Loss of Function Conformational Diseases and are therefore 
excellent targets for the treatment with compounds able to specifically rescue the misfolded 
protein (e.g. pharmacological chaperones), increasing their steady-state levels and 
concomitantly restoring protein function. The features of some of the disease-causing 
variants found in CBS deficient patients allows also to classify CBS deficiency as a 
Conformational Disease and CBS variants as potential targets for rescuing with small 
molecular weight compounds. 
Previous work developed by the Metabolism and Genetics group pointed out that the 
rescue of the p.R336C CBS variant could be achieved by thiol compounds such as CySH and 
MEG.  
Facing the fact that the CBS polypeptide sequence presents 28 Arg residues with five 
of them being involved in R>C disease-causing substitutions, namely the p.R18C, p.R121C, 
p.R336C, p.R369C and p.R491C, the main aims of this project were to: 
1. Clarify the molecular mechanism underlying the increase in the enzyme activity of 
several R>C CBS variants, namely R18C, R121C, R164C, R336C, R369C and 
R491C, in the presence of thiol compounds; 
2. Understand whether the localization of the R>C substitution in the protein sequence 
modulates the observed effect. 
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3. Material and Methods 
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3.1. Production of mutant CBS expression constructs 
Site directed mutagenesis is a powerful tool to introduce specific DNA mutations. 
This in vitro procedure requires the synthesis of a short DNA primer, containing the desired 
mutation and a sequence complementary to the template DNA (which must be dam 
methylated), so it can hybridize with the target DNA sequence of interest.  
Recombinant wild-type (WT) and variant CBS proteins were produced using the 
pET28b expression vector (Clontech Laboratories). The CBS WT cDNA (GenBank 
IDBC007257.1), cloned into the EcoRI and XhoI sites of the pOTB7 vector (Thermo 
Scientific) was used to produce the expression construct (pET28b-6xHis-pepT-hCBSWT) as 
previously described (Mendes, Colaço et al., 2014). The desired mutations were introduced 
by site-directed mutagenesis using the NzyMutagenesis Kit (Nzytech) and the specific 
mutagenic oligonucleotides (Metabion) described in Table 2.  
 
 
Table 2 – Oligonucleotides used for the site directed mutagenesis reaction 
CBS variant DNA change Primer Sequence (5’-3’) 
p.R18C c.52C>T R>C18F 
R>C18R 
GGCTGCCCCCACTGCTCAGGGCCACACTCG 
CGAGTGTGGCCCTGAGCAGTGGGGGCAGCC 
    
p.R121C c.361C>T R>C121F 
R>C121R 
GGAGCGTGAAGGACTGCATCAGCCGC 
GCGGCTGATGCAGTCCTTCACGCTCC 
    
p.R164C c.490C>T R>C164F 
R>C164R 
GGCAGTGAGGGGCTATTGCTGCATCATCG  
CGATGATGCAGCAATAGCCCCTCACTGCC 
 
p.R336C 
 
c.1006C>T 
 
 
R>C336F 
R>C336R 
 
GGCGTTCACCTTTGCCTGCATGCTGATCGCG 
CGCGATCAGCATGCAGGCAAAGGTGAACGCC 
 
p.L338P 
 
c.9858T>C L338P-F 
L338P-R 
 
CCTTTGCCCGCATGCCGATCGCGCAAGAGG 
CCTCTTGCGCGATCGGCATGCGGGCAAAGG 
p.R369C c.1105C>T R>C369F 
R>C369R 
GCAGGAGGGCCAGTGCTGCGTGGTCATTCTGC 
GCAGAATGACCACGCAGCACTGGCCCTCCTGC 
    
p.R491C c.1471C>T R>C491F 
R>C491R 
GCAGTTCAAACAGATCTGCCTCACGGACACG 
CGTGTCCGTGAGGCAGATCTGTTTGAACTGC 
 
p.R491H c.1472G>A R>H491F 
R>H491R 
GCAGTTCAAACAGATCCACCTCACGGACACG 
CGTGTCCGTGAGGTGGATCTGTTTGAACTGC 
Note: Mutagenic oligonucleotides are underlined.  
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The mutagenesis reaction was performed using the buffer supplied by the 
manufacturer in a final volume of 50 l containing 125 ng of each primer, 40 M each 
dNTPs, 60 ng of template DNA and 2.5 U of NzyProof DNA polymerase (Nzytech). DNA 
amplification was performed on a PCR Express Thermocycler (Hybaid) using the template 
program described in Table 3. Whenever necessary, in step 2 the hybridization temperature 
was changed according to the Tm of the primers (62ºC) as well as the elongation temperature 
(72ºC). 
 
 
Table 3 – Amplification program utilized for site directed mutagenesis 
Step Number of cycles Temperature (ºC) Time (min) 
1 1 95 2 
 
2 18 95 
60 (62)1 
68 (72)1 
1 
1 
1.5/kb DNA template 
 
3 1 68 15 
1Changes in temperature.  
 
 
The DNA was digested with DpnI, to degrade the parental methylated DNA (WT), 
and the amplified product was introduced into ultra-competent E. coli cells (NzyStar cells; 
Nzytech). The transformed cells were grown on solid Luria-Bertani broth (LB) supplemented 
with kanamycin (50 mg/L; LB/Kan). After incubation overnight (ON), at 37ºC, one isolated 
colony was chosen to inoculate 10 mL of LB/Kan which was further incubated ON, at 37ºC, 
under constant stirring of 140 rpm. The bacterial culture was used to obtain a cellular pellet 
from which the plasmid DNA was purified.    
The authenticity of mutagenesis was verified by DNA sequencing. This technique 
also allowed excluding for unwanted and unspecific mutagenic events. 
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3.2. Expression of WT and Variant Proteins in E. coli 
To obtain the CBS proteins under study in high yields, a prokaryotic expression 
system and the pET28b expression vector were used. The pET28b vector (Figure 7) presents 
upstream the multiple cloning site (MCS): (1) the promoter T7 recognized by the RNA 
polymerase of Escherichia Coli phage 7; (2) a six CAT codon sequence, which encodes a 
small peptide chain of 6 histidine residues (6xHis Tag); (3) a thrombin cleavage site (Leu-
Val-Pro Arg-↓-Gly-Ser; pepT) located after the 6xHis Tag and before the recombinant 
protein starting codon, allowing 6xHis Tag removal; (4) a ribosome binding site (RBS) 
sequence and (5) the start ATG codon. This vector is further comprised by the T7 terminator 
(downstream the cloned CBS WT cDNA), the LacI gene sequence that assures an efficient 
promoter repression by the repressor lac, the pBR322 replication origin f1, and the 
kanamycin resistance gene that assures the selection of this vector using the appropriated 
culture medium. 
 
 
Figure 7 – Schematic representation of the pET28b vector. The figure shows the: Multiple Cloning 
Site (MCS), T7 promoter, six CAT codon sequence, thrombin cleavage site, Ribosome Binding 
Sequence (RBS) and the start ATG codon (adapted from (http://www.snapgene.com/ 
resources/plasmid__files/pet_and_duet_vectors_(novagen)/pET-28b(+)/, 14-11-2015)). 
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The obtained mutant CBS constructs were used to transform competent E. coli BL21 
(DE3) cells. 
To produce the recombinant CBS proteins (WT and variants) 10 mL of LB/Kan was 
inoculated with an isolated colony. After ON growth, at 37ºC, under constant stirring of 140 
rpm, the culture was used to inoculate 1 L of LB/Kan. A supplement of 75 mg of δ-
aminolevulinic acid (Sigma-Aldrich) was also introduced in the medium, as this compound 
is the biosynthetic precursor of Heme (Kang et al., 2012) and essential cofactor for CBS 
activity and folding (Majtan et al, 2008). The culture was incubated at 37ºC, under a constant 
stirring of 140 rpm until an Abs600nm of 0.45-0.55. Protein expression was then induced by 
addition of 0.5 mM isopropyl-β-D-1-thiogalactopyranoside (IPTG; Nzytech). After 4h of 
incubation at 27ºC under the constant stirring of 140 rpm, the E. coli cells were harvested by 
centrifugation at 2,057 g, for 10 min, at 4ºC. The obtained cellular pellet was stored at -20ºC, 
until usage (no longer than 1 day). 
 
 
 
3.3. Purification of WT and Variant Proteins 
The selective isolation and purification of enzymes and other biologically important 
macromolecules by affinity chromatography exploits the unique biological property of these 
proteins to bind ligands specifically and reversibly (Cubtrecasas et al., 1968). The protein to 
be purified is passed through a column containing an insoluble polymer or gel to which a 
specific competitive inhibitor or ligand has been covalently attached. Proteins not exhibiting 
appreciable affinity for the ligand will pass through the column, whereas those which 
recognize the inhibitor will be retarded to an extent related to the affinity constant under the 
experimental conditions. In this work, the recombinant proteins present N-terminally a 6xHis 
tag with high affinity for metal ions (such as Ni2+), allowing protein purification by 
immobilized metal affinity chromatography (IMAC) using a Ni2+-chelating resin (Ni-NTA; 
Qiagen). To purify the expressed proteins, the E. coli BL21 (DE3) cells were resuspended in 
10 mL (for 1 L of culture) of Buffer A (50 mM potassium phosphate, 300 mM KCl, pH 7.0), 
10% glycerol, 1 mg/mL lysozyme (AppliChem), 1 mM phenylmethylsulfonyl fluoride 
(PMSF) (Merck) and a small amount of DNAse (AppliChem). After 30 min incubation on 
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ice, the cells were disrupted by 3 cycles of ultra-sonication during 60 seconds, with a 50% 
duty free cycle (Vibra Cell sonicator; Sonics Materials). The cell lysate was centrifuged at 
12,857 g, for 40 min, at 4ºC, obtaining an insoluble (pellet) and a soluble (supernatant) 
fraction. To the soluble fraction, imidazole (Merck) and β-mercaptoethanol (Applichem) 
were added to a final concentration of 10 mM each. The Ni-NTA resin (500 µL resin per 10 
mL of soluble lysate fraction) was previously equilibrated with successive washes of: 1 
volume Milli-Q water (3x) and 1 volume Buffer A containing 10 mM imidazole (2x). 
Between washes, the resin was centrifuged at 425 g, for 2 min, rejecting the supernatant. 
After resin equilibration, the soluble lysate fraction was added to the equilibrated resin and 
the suspension was incubated at 4ºC, for 1 h, under constant stirring of approximately 100 
rpm. After this time period, the solution was loaded into a polypropylene conic column (poly-
prep; Bio-Rad) and the flow-through was collected. The purification process was performed 
at 4ºC, using a gradient of Buffer A with increasing imidazole concentrations: 20 mM (2x 5 
mL), 50 mM (2x 5 mL), 75 mM (5x 500 L) and 500 mM (5x 500 L). To remove the 
imidazole from the samples, the fractions corresponding to the eluted protein (500 mM) were 
pooled and loaded into a PD-10 Column (GE-Healthcare) previously equilibrated with Buffer 
A. The recombinant proteins were recovered with Buffer A and quantified using the Bradford 
colorimetric reagent (Bradford MM, 1976) from Bio-Rad and Bovine serum albumin (BSA; 
Calbiochem) as the standard at the final concentrations of 1, 2, 4, 8, and 10 µg/mL. 
Absorbance was measured at 595 nm in a Hitachi spectrophotometer (Model U-2000). All 
assays were performed in triplicate to assure precision. 
When necessary samples were concentrated by ultrafiltration using an Amicon Ultra 
15 centrifugal filter device (MWCO 30 kDa; Millipore). The samples were centrifuged at 
3,220 g, for 5 min, at 4ºC, until a final volume of approximately 1 mL. Between each 
centrifugation, the solution was softly resuspended to desorb protein that might accumulate 
at the filter membrane. The obtained protein was stored at -80ºC until its usage. 
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3.4. Characterization of recombinant proteins 
 
 3.4.1. SDS-PAGE Analysis 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) is a 
technique performed on denaturing polyacrylamide gels. In this system, the proteins are 
separated according to their molecular mass. SDS-PAGE is a powerful tool to evaluate not 
only the protein’s molecular mass, but also the purity grade of protein extracts. SDS is a 
negatively charged detergent that dissolves hydrophobic molecules. Thus, SDS denatures the 
proteins and confers them a negative charge allowing the proteins to move from the cathode 
(negatively charged) to the anode (positively charged). 
In our work, the discontinuous system of Laemmli (Laemmli, 1970) was used. This 
system utilizes a stacking gel (4%)  and a resolving gel (different concentrations) and three 
different buffers: (i) a stacking buffer (Tris.HCl 0.125 mM, pH 6.8, SDS 0.1%); (ii) a 
resolving buffer (Tris.HCl 0.375 mM, pH 8.8, SDS 0.1 %) and; (iii) a running buffer (Tris 3 
g/L; glycine 14.4 g/l; SDS 0.1 %, pH 8.3). This discontinuous Tris-glycine buffer system is 
the most suitable for separation of proteins with molecular masses exceeding 20 kDa. Sample 
separation was performed on a mini-vertical electrophoresis system Hoefer SE245 (GE 
Healthcare).   
The samples were applied in a final volume of 20-25 µL, being previously prepared 
in loading buffer (Tris.HCl 0.24 M pH 6.8, glycerol 40%, SDS 8%, bromophenol blue 0.02%, 
β-mercaptoethanol 25%) and denatured at 95ºC for 5-10 minutes. 
After electrophoresis, the proteins were visualized by staining with Brilliant Blue 
Coomassie R250 (Sigma). To evaluate the molecular mass of the recombinant proteins,  
protein molecular mass markers were used, namely the Low Molecular Weight (LMW) 
Protein Marker (Nzytech; 18.5, 26, 32, 40, 48, 66 and 96 kDa) and NzyColour Protein Marker 
II  Prestained Protein Ladder (Nyztech; 11, 17, 20, 25, 35, 48, 63, 75, 100, 135, 180, and 245 
kDa). 
The purity grade and molecular mass of the produced recombinant proteins were 
evaluated using a 10% polyacrylamide resolving gel. Protein purity was assessed by 
densitometric analysis, using the ImageJ 1.42q software (National Institutes of health; USA). 
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3.4.2. Assay of Enzymatic Activity  
The enzyme activity of recombinant CBS was determined in a reaction volume of 
110 μL, containing 100 mM Tris HCl pH 8.6, 5 mM L-Ser and 5 μg of WT CBS or 10 μg of 
the variant forms. To prevent the unspecific formation of Cth, 5 mM EDTA (Smith et al., 
2012) were also included in the reaction mixture. The reaction was started by the addition of 
2.7 mM L-Hcy, prepared from L-Hcy thiolactone hydrochloride (Sigma) (Mendes, Colaço et 
al., 2014). After 30 min at 37°C, the enzymatic reaction was stopped by the addition of 110 
µL ethanol:acetic acid (98:2) solution. After centrifugation at 10,621 g, during 5 min, at 4ºC, 
the supernatant was used to determine the amount of the produced L-Cth. The enzymatic 
activities were expressed as nmol of Cth formed per mg of protein per hour at 37ºC (nmol 
Cth.h-1.mg-1). The enzymatic assays were performed in the absence or in the presence of 1 
mM PLP or 1 mM MEG (pre-incubation at 37ºC for 1h). Three independent experiments 
were performed for all the assays.  
 
 
3.4.3. Quantification of Cystathionine by HPLC 
To determine the activity of the recombinant purified CBS proteins, it was necessary 
to develop a method to quantify the L-Cth produced during the enzyme reaction. High 
pressure liquid chromatography (HPLC) with fluorimetric detection is usually associated 
with high sensitivity, linearity and reproducibility. Therefore, due to the availability of this 
technique in our laboratory (Met&Gen group), a method to detect L-Cth by HPLC after 
derivatization with O-phthaldialdehyde (OPA) and fluorimetric detection was implemented.  
The amount of L-Cth produced after 30 min was quantified as previously described 
(Ravanel et al., 1995), using an HPLC Waters System equipped with a fluorimeter, and a 
Gemini C18 column  (150x4.6 mm, 5 μm particle size; Phenomenex). The mobile phase 
consisted of buffer B (85 mM sodium acetate, pH 4.5; 6% acetonitrile) and Buffer C (60% 
acetonitrile) pumped at 1 mL.min-1 flow rate. A linear gradient of 40 to 80% solvent C (0-6 
min), 80% solvent C (6-9 min), 80-40% solvent C (9-10 min), 40% solvent C (10-12 min) 
was used. The injected volume was 5 L and the OPA derivatives were detected by 
measuring the fluorescence at λexc= 340 nm and λem= 455 nm. During running, the column 
was maintained at 40ºC. 
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Cystathionine solutions at different concentration (7.81, 15.6, 31.25, 62.5, 125, 250 
and 500 µM) were used to determine the detection limit and linearity of the method. 
Norvaline was used as the internal standard.  
 
 
3.4.4. Limited Proteolysis 
Proteolysis of native proteins can be limited, and the rate of digestion of peptide bonds 
depend on several parameters, the most important of which is the capability for local 
flexibility of the polypeptide chain in the region of the scissile bond (Hubbard, 1998). 
Proteolytic enzymes can therefore be used as probes of flexible or exposed regions of a 
polypeptide chain, including conformational shifts as those elicited by ligand binding 
(Fontana et al, 2004; Ellison et al, 1995). Usually proteases, such as trypsin, with a wide 
proteolytic activity, should be used.  
Limited proteolysis of WT and CBS variants was performed at 25ºC in buffer A, with 
a final protein concentration of 0.6 mg/mL and a trypsin (Sigma):CBS ratio of 1:100 
(mass/mass), in the absence or presence of 1 mM cysteamine, 1 mM MEG or 2.7 mM PLP. 
At different time points (0, 2, 5, 10, 15, 30, 45, 60 and 120 min), 20 µL aliquots of the reaction 
were mixed with soybean trypsin inhibitor (Sigma) at a protease:inhibitor ratio of 1:1.5 (by 
mass). Samples were loaded on a 10% polyacrylamide gel as described above. Gels were 
stained with Coomassie brilliant blue R250 and the band corresponding to the full-length 
protein was quantified by densitometry using ImageJ 1.42q software. 
 
 
3.4.5. Differentiation Scanning Fluorimetry 
Differential Scanning Fluorimetry (DSF) is a thermal shift assay where the 
temperature at which a protein goes from well-defined structure to a disorder state is 
determined. This technique is based on monitoring changes in the fluorescence signal of 
SYPRO orange dye, as it interacts with the hydrophobic residues of a protein undergoing 
thermal unfolding (Figure 8) and allows determination of the melting temperature (Tm), the 
midpoint of the protein melting curve. The dye’s fluorescence signal is quenched in the 
aqueous environment of a properly folded protein, but becomes unquenched when exposed 
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to the protein’s hydrophobic core upon unfolding. The Tm will increase in the presence of 
ligands that bind to the protein stabilizing it. 
 
 
 
 
Figure 8 – Schematic representation of the Thermal Shift Assay (adapted from Argonne National 
Laboratory, Biosciences Division - Molecular and Systems Biology; http://www.bio.anl.gov/ 
molecular_and_systems _biology/Sensor/sensor2.html, 06-08-2015). 
 
 
The WT and CBS variants were centrifuged (10,621 g, for 10 min, at 4ºC) to remove 
insoluble aggregates. Proteins were diluted in buffer A to a final concentration of 0.05 
µg/mL. Sypro Orange (Invitrogen; 5000× stock solution) was used at a final 2.5× working 
concentration. Stabilizing compounds (1 mM Cysteamine, 1 mM MEG and 1 mM PLP) were 
tested without and with pre-incubation with the proteins, in Buffer A, for 1h at 37ºC.  
The DSF assay was performed on a C1000 Touch thermal cycler equipped with a 
CFX96 optical reaction module (Bio-Rad) in a final volume of 50 L. The PCR plate was 
sealed with Optical-Quality Sealing Tape (Bio-Rad) and centrifuged at 500xg, at 4 ºC, for 3 
min. DSF was carried out by increasing the temperature from 20 to 90 ºC, at 1 ºC/min. The 
obtained results were analyzed using GraphPad Prism 6 software (GraphPad, Software, Inc). 
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3.4.6. Modification of Recombinant proteins with PEG-Mal 
Polyethylene glycol (PEG) is a molecule frequently used as a protein PEGylation 
reagent. PEGylation is the process of covalently attach the polyethylene glycol polymeric 
chain – which can have different molecular weight – to another molecule, such as proteins. 
PEGylation was originally designed to improve the pharmacokinetic profile of protein 
therapeutics (Fried et al, 2002; Hadziyannis et al, 2004; Talal et al, 2006). In our work, PEG-
Maleimide (PEG-Mal) was used to covalently attach PEG to the Cys residues of the CBS 
proteins through the maleimide moiety. In fact, N-ethylmaleimide (NEM) is an alkylating 
reagent that reacts with sulfhydryls (–SH; such as that found in Cys) to form stable thioether 
bonds (Smyth D et al., 1960). 
In our work, PEG-Mal with a polymeric chain of 5000 (PEG5000) was used (Lu et al., 
2001). The PEG-Mal-modified protein migrates more slowly on SDS-PAGE than those of 
the unmodified protein, allowing to monitor for the number of available Cys residues 
accessible to modification by PEG-Mal. 
PEG-Mal (Sigma-Aldrich) was freshly prepared in buffer A. In all cases, samples 
were subjected to a pulse of a molar excess of PEG-Mal. Different temperatures and 
incubation times were tested to optimize the reaction. 
To test MEG binding to CBS free Cys residues, a pre-incubation with 1 mM MEG 
for 1h at 37ºC was performed. MEG was further removed from the sample using a MiniTrap 
G-25 column (GE-Healthcare), and the resulting protein was then PEGylated with PEG-Mal. 
Samples were loaded on 7.5% or 10% denaturant polyacrylamide gel as described 
above. Gels were stained with Coomassie brilliant blue R250, and the band corresponding to 
the full-length protein was quantified by densitometry using ImageJ 1.42q software. 
 
 
3.4.7. Evaluation of –SH groups by DTNB 
Following the PEG-Mal modification, the free Cys residues were evaluated using the 
Ellman’s reagent, 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB). This reagent is often used to 
determine the number of free –SH groups in proteins, cells and plasma by absorption 
measurements (Ellman, 1959; Robyt et al, 1971; Sedlak et al, 1968). The procedure is based 
on the reaction of the thiol group with DTNB (Figure 9) to produce an equivalent amount of 
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the yellow chromophore 5-thio-2-nitrobenzoic acid (TNB2-), which absorbs at 412 nm. 
However, it must be noticed that the DTNB method could underestimate the concentration 
of free thiol groups in a protein due to its incomplete reaction. 
 
 
 
Figure 9 – Reaction of DTNB with a thiol compound (R–SH). 
 
  
The DTNB (Sigma-Aldrich) solution was prepared at 1 mM in Phosphate buffer 50 
mM, pH 8.0. The reaction was performed in a final volume of 1 mL, containing DTNB at 
100 M (final concentration). Samples (before and after PEG-Mal modification) were 
incubated at RT, for 5 min. The absorbance was measured at 412 nm. Assays were performed 
in triplicate. 
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4. Results and Discussion 
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4.1 Characterization of the R>C CBS variant proteins 
As referred previously, CBS contains in its sequence 28 Arg residues, which are 
localized all over its sequence (Table 1; Figure 3A). In order to understand if the rescue of 
the activity of R>C CBS variants depends on the localization of the affected residue, six 
amino acid residues  presenting different ASA values and domain localization were selected 
for mutagenesis, namely the R18, R121, R164, R336, R369 and R491 (Figure 3B). 
Additionally, an equivalent R>H substitution in position 491 was also studied as a control 
(p.R491H). 
The variant proteins were produced in a prokaryotic expression system, already in 
use in the laboratory. Functional and structural studies were performed with the purified 
recombinant proteins in the absence and in the presence of aminothiol compounds, namely 
CySH and MEG.   
 
 
4.1.1. Production of the R>C and R>H expression constructs 
The desired mutations were successfully introduced in the CBS cDNA cloned in the 
expression vector pET28b(+) (Invitrogen) by site-directed mutagenesis using the template 
program described in the Material and Methods section (Table 3). However, for the 
introduction of the p.R121C and p.R164C mutations an adjustment to the hybridization and 
elongation temperature was necessary, since no colonies were obtained after E. coli 
transformation. Following DNA purification, sequencing analysis showed the correct 
introduction of the desired DNA changes, which are presented in Figure 10. The complete 
sequencing of the mutated cDNAs further allowed verifying that no additional mutations 
were introduced (data not shown). 
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Figure 10 – Partial sequence panels of the CBS cDNA after site-directed mutagenesis. Arrows 
indicate the position of the single base substitution in the cDNA sequence. For each mutation, the 
wild-type and mutated codon is shown with the base change underlined. 
  
 
4.1.2. Expression and purification of recombinant WT and CBS variants 
Using the expression conditions described in Material and Methods section, we were 
able to produce the recombinant CBS variant proteins in the soluble fraction of E. coli lysates. 
In Figure 11, an SDS-PAGE representative of the elution profile of a CBS variant protein 
(p.R18C) is shown. The CBS proteins were eluted with 500 mM imidazole mostly in the first 
three fractions (Figure 11, lanes 4-6).  
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Figure 11 – SDS-PAGE analysis of the purification of p.R18C variant. The recombinant CBS 
proteins were purified by immobilized metal affinity chromatography using a gradient of imidazole 
concentration: 10 mL of 20 mM (1), 10 mL of 50 mM (2), 2.5 mL of 75 mM (3), and 5 x 500 L of 
500 mM (4-8). (1) NzyColour protein marker II (Nzytech); (9) Purified CBS recombinant protein 
after removal of imidazole by gel filtration (using a PD-10 column). In each lane an aliquot of 16 L 
of each imidazole elution fraction was applied. 
 
 
For all the expressed CBS proteins, the molecular mass of the main band 
corresponded to 63 kDa (Figure 12), which is the estimated molecular mass of the 
recombinant CBS proteins. Interestingly, for all the recombinant CBS proteins (WT and 
variants), after gel filtration chromatography we could observe a decrease of the 
contaminating proteins resulting in a high purity grade (Figure 11, lane 9). 
 
 
 
Figure 12 – SDS-PAGE analysis of the purified CBS recombinant proteins (WT and variants) after 
immobilized metal affinity chromatography (IMAC). The recombinant CBS proteins are indicated by 
an arrow. 
 
 
42 
 
However, when comparing with the WT protein, the purity grades and yields of the 
CBS variants varied significantly from 7% (p.R164C) to 58% (p.R121C) (Figure 12 and 
Table 4). Due to the low yield and low purity grade of the p.R164C variant, no further studies 
were performed for this protein. 
 
 
Table 4 – Yield and purity grade of the produced recombinant CBS proteins after IMAC purification 
 Protein 
(g/mL) 
Yield 
(mg/L culture) 
Purity grade 
(%) 
 
WT 597.94 478.35 80  
p.R18C 674.76 256.41 38  
p.R121C 475.24 275.64 58  
p.R164C 303.17 21.22 7  
p.R336C 529.24 278.04 48  
p.R369C 478.79 220.24 46  
p.R491C 662.67 271.69 41  
p.R491H 811.71 373.39 46  
 
 
 
4.1.3. Conformational flexibility of the R>C recombinant proteins 
The susceptibility of WT and CBS variants to limited proteolysis by trypsin was 
followed over time. This allowed us to probe the changes occurring, not only in the native 
folding of the enzyme which are caused by the mutations, but also to assess the effect of two 
aminothiol compounds on the tertiary structure of the variant proteins. As such, the CBS WT 
and R>C variant proteins were incubated for 1h at 37°C in the presence and absence of CySH 
and MEG. As a control, the p.R491H was also tested. After incubation, trypsin was added 
and at different time points, aliquots were collected and analyzed by SDS-PAGE, as shown 
in Figure 13. The percentage of remaining full-length enzyme was followed by densitometric 
analysis. The obtained values were plotted and fitted to a single exponential decay equation 
(Figure 14), allowing to obtain the decay constant of proteolysis (kP) and the t1/2 (time at 
which 50% of the full-length protein remains intact) (Table 5). 
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Figure 13 – SDS-PAGE analysis of the time-course for the limited proteolysis by trypsin of p.R491C 
variant. At different time points (0 to 120 minutes) aliquots were taken and analyzed on a 10% SDS-
PAGE. See text for details. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14 – Time-course for the limited proteolysis by trypsin of WT CBS and variant proteins. Data 
represent the mean of two independent experiments. Data were fitted to a single exponential decay 
equation to obtain the decay constant of proteolysis (kp). The polyacrylamide gel presents the aliquots 
from the different time points (0, 2, 5, 10, 15, 30, 45, 60 and 120 min). 
 
 
In the absence of the studied aminothiol compounds, and when comparing to the WT, 
the R>C variant proteins p.R18C, p.R121C and p.R336C presented an increase in the kP, with 
the corresponding decrease in t1/2 (Figure 14, Table 5) value. 
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Table 5 – Proteolysis rate (kp) and half-life (t1/2) of WT and variant forms of CBS 
 
 
 
 
Interestingly, the p.R369C and p.R491C variants showed a mild change in the kP, 
while the p.R491H presented a lower kP value (Figure 14, Table 5).  As expected, and taking 
into consideration that the R>C variants selected for our study are disease-causing mutations, 
these data indicate that a change in the native folding and/or conformational flexibility of the 
enzymes, caused by the amino acid change, might have occurred.  
After incubation with the aminothiol compounds CySH and MEG, the variant 
proteins showed a change in kp and t1/2 with different trends for different variants. As shown 
in Table 5 and Figure 14, in the presence of CySH the WT and the majority of the variant 
proteins (except the p.R18C and p.R121C) increased their kp and consequently decreased 
their t1/2 indicating a higher susceptibility for proteolysis in the presence of this aminothiol.  
However, in the presence of MEG only the p.R18C and p.R336C decreased their kp 
significantly, while the p.R121C showed only a moderate decrease, suggesting that the 
aminothiol MEG may stabilize these variants. The p.R369C and p.R491H variants showed a 
lower degree of proteolysis (higher kp), while the WT and p.R491C did not change 
significantly (Table 5, Figure 15). 
 
 
 
 
 kp 
 (min-1) 
 
 
t1/2  
(min) 
 - CySH MEG  - CySH MEG 
WT 0.027 0.39 0.038  25.6 2.70 24.07 
R18C 0.14 0.052 0.054  5.00 13.2 12.8 
R121C 0.57 0.25 0.46  1.22 2.74 1.49 
R336C 0.20 0.24 0.046  3.50 2.84 17.24 
R369C 0.032 0.15 0.077  21.9 4.66 9.02 
R491C 0.034 0.089 0.026  26.7 7.75 27.1 
R491H 0.020 0.071 0.042  34.4 9.74 16.71 
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Figure 15 – Proteolysis rate of the WT and variant proteins in the absence (black columns) and in the 
presence of 1 mM CySH (blue columns) or 1 mM MEG (green columns). The dotted line indicates 
the kp for the WT CBS in the absence of thiol compounds. See text for details. 
 
 
 
The data gathered indicate that incubation with the studied aminothiol compounds 
lead to a change in the conformation of the studied variant proteins probably by an interaction 
of these compounds with specific R>C residues, thereby altering their proteolysis rate, and 
thus leading to more stabilized or more destabilized proteins, depending on the localization 
of the affected residue. 
 
 
4.1.4. Thermal stability of the R>C recombinant proteins 
 Differential scanning fluorimetry (DSF) was employed to study the thermal stability 
of the WT and variant CBS proteins. Using DSF and a specific fluorescent dye (Sypro 
orange), which binds to hydrophobic residues, we were able to follow protein unfolding and 
determine the respective Tm, i.e. temperature at which half of the protein is unfolded (Figure 
16). 
The DSF thermal denaturation curves for WT and variant CBS proteins show two 
transitions (Figure 16), allowing the estimation of Tm1 and Tm2 corresponding to the thermal 
denaturation of the C-terminal and catalytic domain, respectively (Table 6). 
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In the three assay conditions tested – in the absence of aminothiol compounds, in the 
presence of aminothiol compounds with pre-incubation, and in the presence of aminothiol 
compounds but without pre-incubation –  all the studied variants presented Tm1 and Tm2 values 
lower than the WT (Tm  >2ºC). The only exception was the p.R369C variant that presented 
a decreased Tm1 but a normal Tm2. From the thermal stability data gathered in the presence of 
the studied aminothiol compounds for the CBS WT and variants, it is possible to observe that 
only the p.R336C variant is sensitive to the presence of the aminothiol compound MEG, 
increasing the stability of the catalytic domain (corresponding to Tm2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16 – Thermal unfolding of WT and p.R491C CBS proteins monitored by differential 
scanning fluorimetry (DSF). Data represent the mean of three assays. Experimental data is 
represented by the open symbols and the line corresponds to non-linear regression analysis using a 
biphasic equation. See text for details. 
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Table 6– Melting temperature (Tm) of WT and variant forms of CBS, in the absence (-) and presence of 1 mM of CySH or MEG, 
determined by differential scanning fluorimetry 
 
 No pre-incubation  Pre-incubation 
 Tm1  Tm2  Tm1  Tm2 
 (-) CySH MEG  - CySH MEG  (-) CySH MEG  - CySH MEG 
WT 52 52 -  63 64 -  52 48   63 60 - 
p.R18C - - -  - - -  - - -  - - - 
p.R121C 44 44 44  51 51 51  45 45 44  52 51 52 
p.R336C 41 - 43  54 - 60  43 44 44  51 51 60 
p.R369C 47 45 45  60 58 58  49 47 49  61 59 59 
p.R491C 39 42 42  57 58 59  40 42 42  59 60 59 
p.R491H - - -  - - -  - - -  - - - 
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4.1.5. Assessment of MEG binding by PEG-Mal modifications 
As stated in Material and Methods section, the assessment of the protein free –SH 
groups was performed using PEG-Mal. This polymeric compound is able to react covalently 
with free –SH groups, leading to PEGylated forms of the protein with an increase of ~5 kDa 
for each molecule of PEG-Mal added. This technique was used to determine if the tested 
aminothiol compounds were able to specifically react with the Cys residues of the R>C 
variant proteins, thus decreasing the available free –SH groups. However, to the limited 
amount of purified CBS proteins (WT and variants), an optimization of the PEG-Mal 
modification was firstly performed using instead a recombinant form of the wild-type S-
adenosyl-homocysteine hydrolase (SAHH). 
 
 
  4.1.5.1 Optimization of PEG-Mal modification with SAHH 
As referred above, to optimize the conditions of the PEG-Mal reaction, and in order 
to save the recombinant CBS protein for later studies, a recombinant protein available in the 
laboratory, SAHH, was used as it has a high expression rate. The protein SAHH has 10 Cys 
residues in its structure (similar to CBS, which presents 11 Cys residues) and a molecular 
mass of 43 KDa. After SAHH..PEGylation, 10 different protein forms with MM ranging 
from 48 to 93 kDa were expected (48, 53, 58, 63, 68, 73, 78, 83, 88 and 93 kDa). 
 The first parameter to be optimized was the incubation time. For this, we used a 
temperature reaction of 4ºC, constant stirring of 140 rpm and 1:400 protein:PEG-Mal ratio 
(by mass) during different reaction times (0, 30, 60 and 120 minutes). As shown in Figure 
16, the SAHH protein immediately reacted with PEG-Mal, leading to additional 5 bands of 
increasing MM, visible in a 10% SDS-PAGE.  The band corresponding to the WT SAHH 
decreases its intensity with time, while additional bands of higher MM became visible as 
PEG-Mal molecules bind to a Cys residue. At 120 min, a total of 6 additional bands were 
observed (Figure 17). 
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Figure 17 – SDS-PAGE analysis of PEG-Mal binding to S-adenosyl-homocysteine hydrolase 
(SAHH) at 4ºC.  SAHH was incubated with 1:400 protein:PEG-Mal ratio (by mass) at 4ºC for 0, 30, 
60 and 120 minutes, under constant stirring of 140 rpm. The unmodified SAHH protein presents a 
molecular mass of 43 kDa. 
 
 
Interestingly, it is possible to observe that the binding reaction of PEG-Mal to protein 
seems to be instantaneous, as observed for the presence of various bands of higher molecular 
mass (Figure 17, lane 0’ and Figure 18, lane 0’) than the SAHH protein (43 kDa; Figure 18, 
lane 0’*). 
 In order to increase protein PEGylation rate, we then tested a higher temperature 
reaction (25ºC; RT) and more time-points. As shown in Figure 18, at RT a higher number of 
additional bands was obtained after 10 min of reaction. After this time period, the bands 
intensity decreased probably due to the aggregation of the protein. 
 
  
 
Figure 18 – SDS-PAGE analysis of PEG-Mal binding to S-adenosyl-homocysteine hydrolase 
(SAHH) at 25ºC (RT).  SAHH was incubated with 1:400 protein:PEG-Mal ratio (by mass) at RT for 
0, 5, 10, 15, 30, 60, 90 and 120 minutes, under constant stirring of 140 rpm. 0’* represents SAHH 
with no PEG-Mal added (molecular mass of 43 kDa). 
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To test MEG binding to Cys residues, we pre-incubated SAHH with 1 mM MEG for 
1h at 37ºC and monitored SAHH PEGylation. After removing excess of MEG using gel 
filtration (PD-10 column), the resulting protein was PEGylated with 1:400 or 1:800 
protein:PEG-Mal (by mass) for 0 and 10 minutes, at RT, under constant stirring of 140 rpm. 
The polyacrylamide gel depicted in Figure 19 shows that in the presence of MEG the 
relative intensity of the different bands changed, suggesting a change in the number of 
available Cys residues and indicating that MEG was able to bind to Cys residues, blocking 
their reactivity towards PEG-Mal. 
 
 
 
Figure 19 – SDS-PAGE analysis of PEG-Mal binding to S-adenosyl-homocysteine hydrolase 
(SAHH) after MEG treatment. SAHH was pre-incubated with 1 mM MEG for 1h at 37ºC; after MEG 
removal, SAHH was incubated with 1:400 or 1:800 protein:PEG-Mal (by mass) at RT for 0 and 10 
minutes, under constant stirring of 140 rpm. SAHH with no PEG-Mal added (1, 2); SAHH incubated 
with 1:400 protein:PEG-Mal (by mass) after 0 and 10 min (3 and 4, respectively); SAHH incubated 
with 1:800 protein:PEG-Mal (by mass), after 0 and 10 min (5 and 6, respectively). 
 
 
In order to confirm the results obtained for SAHH PEGylation, assessment of the 
protein free –SH groups, before and after incubation with MEG followed by protein 
PEGylation, was performed using the DTNB assay. This compound upon binding to free –
SH groups produces a chromophore. The analysis of the results obtained with the DTNB 
assays indicate a lower level of free –SH groups after MEG incubation and SAHH 
PEGylation, suggesting that MEG binds to Cys residues in the SAHH protein (data not 
shown). 
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In conclusion, the results obtained suggest that the optimized conditions for the PEG-
Mal reaction are incubation at RT (25ºC) for 10 min and using a 1:400 SAHH:PEG-Mal ratio 
(by mass). 
 
 
  4.1.5.2. PEGylation of CBS WT 
As stated above, the CBS protein has in its structure 11 Cys residues and as such, 11 
bands with MM ranging from 68 to 118 kDa were expected to be observed (68, 73, 78, 83, 
88, 93, 98, 103, 108, 113 and 118 kDa). The conditions of the PEGylation reaction optimized 
for the SAHH protein were then used to monitor CBS PEGylation with and without MEG 
treatment. 
In Figure 20, it is presented the PEGylated CBS WT protein without incubation with 
MEG (panel A) and with pre-incubation with 1 mM MEG, at 37ºC, during 1h (panel B). In 
the absence of MEG, five bands above the 63 KDa of the CBS WT protein are visible (Figure 
20, panel A), corresponding to the PEG-Mal that bonded to the free Cys residues. It must be 
noticed that two large bands with MM between 65 KDa–75 KDa and ≈75 KDa were observed, 
which might correspond to the expected PEGylated forms of 68 and 73 KDa (first band of 
65 KDa>MM<75 KDa) and 78, 83 and 88 KDa (second band of ≈75 KDa). A third band near 
100 KDa might indicate the presence of the PEGylated forms of 93 and 98 KDa. However, 
after incubation with MEG, no significant changes were observed to the SDS-PAGE profile. 
Due to the low resolution of the gel, we were not able to completely exclude a change in the 
electrophoretic profile in the presence of this aminothiol, and therefore this assay should be 
repeated using a gel gradient, which presents a higher resolution. 
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Figure 20 – SDS-PAGE analysis of PEG-Mal binding to cystathionine--synthase (CBS) without 
pre-incubation (Panel A) and after pre-incubation with 1 mM MEG during 1h at 37ºC.  Panel A – The 
CBS WT was incubated with 1:400 or 1:800 protein:PEG-Mal ratio (by mass) at RT for 0 and 10 
minutes, under constant stirring of 140 rpm. CBS WT with no PEG-Mal added (1); CBS WT 
incubated with 1:400 protein:PEG-Mal ratio (by mass) at 0 and 10 min (2 and 3 respectively); CBS 
WT incubated with 1:800 protein:PEG-Mal ratio (by mass) for 0 and 10 min (4 and 5, respectively). 
Panel B – CBS WT after incubation with MEG and with no PEG-Mal (1); CBS WT with MEG, after 
gel filtration (PD MiniTrap) (no PEG-Mal) (2); CBS WT incubated with 1:400 protein:PEG-Mal ratio 
(by mass) for 0 and 10 min (3 and 4, respectively); CBS WT incubated  with 1:800 protein:PEG-Mal 
ratio (by mass) for 0 and 10 min (5 and 6, respectively). 
 
 
 
4.1.6. Enzymatic activity of R>C variants 
 
4.1.6.1. Optimization of an HPLC method for cystathionine quantification 
The enzymatic activity of CBS is determined based on the amount of Cth produced 
in the reaction mixture. Till present, the Cth quantification was based on a GC-FTIR 
technique after extraction and derivatization using the EZ:faast™ Amino Acid Analysis Kit 
(Phenomenex). Besides its low sensitivity, this technique is highly expensive. Therefore, an 
alternative method for detection of Cth using HPLC was optimized based on the technique 
described by Ravanel S and collaborators (Ravanel et al., 1995). 
Using the solvents gradient system as described by the above authors, we performed 
preliminary HPLC assays to confirm the complete resolution between the amino acids used 
in the enzymatic reaction mixture, namely the substrates L-Ser and L-Hcy, the reaction 
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product Cth, and the aminothiol compounds cysteamine and MEG (Figure 21A and B). We 
also tested the use of norvaline as the internal standard (Figure 21B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21 - HPLC chromatograms of standard solutions. (A) L-serine (L-Ser), MEG, norvaline and 
L-homocysteine (L-Hcy). (B) Cystathionine. (PI) Cysteamine. See text for details. 
 
 
 
We found that L-Hcy presented an elution time similar to cystathionine (Figure 21A 
and B), which could lead to an incorrect quantification of the reaction product. Therefore, we 
changed the gradient and the running time (15 min), while maintaining the oven temperature, 
the buffers composition and the flow rate. At time zero, the percentage of buffer B was 
decreased from 40 to 25%. The initial linear gradient of 25 to 80% solvent B (previously 40-
80%) was extended to 8 min (previously 0-6 min), then 80% solvent B was maintained till 
11 min and then returned to 25% in 1 min. Using the optimized solvent gradient, a higher 
resolution of L-Hcy and Cth peaks were obtained (Figure 22). 
 
A 
B 
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Figure 22 - HPLC chromatogram of the enzymatic reaction of CBS WT. Norvaline was used as the 
Internal Standard (PI). See text for details. 
 
 
Using the described conditions, the HPLC quantification of Cth revealed to be linear 
(R2 of 0.998) from 7.8 to 500 M Cth, corresponding to an injected amount of 39 pmol to 
2.5 nmol of Cth, as shown in Figure 23. 
 
 
 
 
 
 
 
 
 
 
Figure 23 – Calibration curve of L-cystathionine. Standard solutions were measured by HPLC after 
OPA derivatization and fluorimetric detection. See text for details. The equation of the linear 
regression line and the corresponding correlation coefficient (R2) are presented. 
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4.1.6.2. Enzymatic activity of the R>C CBS variants in the absence and 
in the presence of MEG 
Using the developed HPLC method for Cth quantification, the catalytic activity of 
the WT and variant proteins were determined. The assays were performed in the absence and 
after pre-incubation of the proteins with MEG, at 37ºC during 3h. As shown in Figure 24, 
from the studied variant proteins, only for the p.R121C the HPLC method was unable to 
detect the produced Cth.  
According to our previous studies (Mendes et al., 2015) the p.R336C variant 
presented around 12% of residual activity. Curiously, for the remaining variants their residual 
catalytic activity was higher than the WT. These observations were expected for the p.R18C 
(4.4-fold increase) and for the mutations affecting the R491 residue (R>C and R>H, 9.4- and 
6.7-fold increase respectively), but not for the p.R369C variant (2.9-fold increase). 
In fact, p.R18C was found with 1% of the allele frequency in normal controls in the 
Korean population (Lee et al., 2005) and with a residual activity, when expressed in 
mammalian cells, of 30%. These data leaded to the classification of the p.R18C variant as a 
single nucleotide polymorphism. 
Regarding the mutations affecting the R491 residue, it is well known that amino acid 
changes in the C-terminal regulatory domain usually lead to CBS proteins presenting a higher 
residual activity than the WT protein, since they lead to a protein conformation in a pre-
activated state (Mendes, Santos et al, 2014). 
When compared to the WT CBS, the p.R369C variant presented not only a higher 
residual activity, but also a similar resistance to proteolysis (Table 5 and Figures 14B and 
15). However, its C-terminal domain presented a lower stability (Tm1< 5ºC, Table 6). 
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Figure 24 – Specific enzyme activity of CBS recombinant proteins (WT and R>C variants) in the 
absence (grey columns) and with pre-incubation with 1mM MEG (green columns). The dotted line 
indicates the catalytic activity for the WT CBS without added thiol compound. 
 
 
Interestingly, when incubated with 1 mM MEG for 3h, only the p.R18C and p.R336C 
variants showed an increase in the catalytic activity of 1.3- and 11-fold respectively in respect 
to the enzymatic activity determined in the absence of the aminothiol compound, which 
suggests that the potential stabilizing effect of MEG upon binding to R>C may be specific 
for specific residues.  
The variant proteins who presented an increase (or similar) proteolysis rate after pre-
incubation with MEG, namely the p.R369C, p.R491C and p.R491H, all showed a 0.6-fold 
decrease in their catalytic activity, indicating that for these variants the aminothiol does not 
have an apparent stabilizing effect. 
 
 
 
4.2. Characterization of the p.L388P variant identified in a 
Portuguese CBS deficient patient 
The CBS variant L338P was first identified in 2003 in a Spanish patient (Urreizti et 
al., 2003) with a clinical phenotype of a severe form of classical homocystinuria. In 
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fibroblasts, the enzyme presented only 3.1% of residual activity and was considered non-
responder to Vitamin B6 (6.4% residual activity in the presence of PLP). Previous 
characterization of the p.L388P protein in E. coli lysates showed a residual enzyme activity 
lower than 4%. Additionally, native gel experiments allowed to demonstrate this variant did 
not form tetramers and that monomers were also dramatically diminished, suggesting an 
intrinsic instability in the tertiary structure (Urreizti et al., 2006). 
Recently, our group also identified the p.L338P variant in a Portuguese classical 
homocystinuric patient. This patient has been followed in the Metabolic Unit of Hospital 
Santa Maria, and the clinical phenotype after Vitamin B6 supplementation was suggestive of 
a responsive patient. In order to elucidate the observed clinical evaluation, we initiated the 
expression, purification and characterization of the p.L338P variant. 
 
 
4.2.1. Expression and purification of recombinant WT and p.L388P CBS 
variant 
Using site directed mutagenesis, the c.1013T>C mutation (p.L338P) was successfully 
introduced in the expression construct pET28b-6xHis-pepT-hCBSWT. DNA sequencing 
allowed confirming the presence of the desired mutation (Figure 25) and the absence of 
additional DNA changes.   
 
 
 
Figure 25 – Partial sequence panel of the CBS cDNA after site-directed mutagenesis for the 
introduction in the CBS cDNA of the c.1013T>C mutation encoding for the p.L388P variant of CBS 
protein. The arrow indicates the position of the single base substitution in the cDNA sequence. The 
wild-type and mutated codon are shown with the base change underlined. 
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Using the previously described expression conditions, the recombinant p.L388P 
variant protein was eluted from the Ni-NTA column with 500 mM imidazole (Figure 26).  
 
 
 
Figure 26 – SDS-PAGE analysis of the affinity chromatographic purification of recombinant 
p.L338P variant. Recombinant protein was purified by immobilized metal affinity chromatography 
using a gradient of imidazole concentration: 10 mL of 20 mM (1), 10 mL of 50 mM (2), 2.5 mL of 
75 mM (3), and 5 x 500 L of 500 mM Imidazole (4-8). (MM) Pre-stained protein ladder. (9) Purified 
CBS protein after removal of imidazole by gel filtration (PD-10 column). In each lane an aliquot of 
16 L of each imidazole elution fraction was applied. 
 
 
 
 
As shown in Figure 26, the p.L338P variant was produced in low levels (59.17 µg/L 
culture vs. 597.94 µg/L culture for WT) and with a purity grade of only ≈4% (vs. 80% for WT), 
which precluded its use for proteolysis and DSF assays. The low expression levels indicate 
that the protein will probably be found mainly in the insoluble fraction of the E.coli lysate, 
thus pointing to a protein with a high propensity to aggregate. 
 
 
4.6.4. Effect of PLP on the catalytic activity of the p.L338P variant  
 The low yield obtained for the p.L338P variant already anticipated a variant protein 
with reduced enzymatic activity. In fact, with the developed HPLC method we were not able 
to detect the Cth produced by this variant enzyme, nor in the absence nor in the presence of 
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PLP (Table 7). Interestingly, the WT protein did not significantly change its activity in the 
presence of PLP, as previously reported by our group (Mendes, Santos et al., 2014). 
 
 
Table 7 – Residual enzyme activity of the WT and the p.L338P CBS proteins in the absence and 
presence of PLP 
 
 Specific enzyme activity 
(nmol Cth.h-1.mg-1) 
 -PLP PLP 
(2.7 mM) 
WT 100 92 
p.L338P n.d. n.d. 
Note: the enzymes were pre-incubated at 37ºC, for 1h, in the absence and in the presence of 
1 mM PLP. (n.d.) not detected. 
  
 
The low yield of the p.L338P variant did not allow the biochemical and structural 
characterization of this protein. Changes in the expression procedure should be implemented 
(higher culture volume and/or increased expression time) in order to obtain the variant protein 
with a good purity grade and in high amounts to perform the characterization studies. 
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5. General Discussion 
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In this work, we studied the effect of two aminothiol compounds, CySH and MEG, 
on the partial repair of five CBS variants carrying an R>C substitution: p.R18C, p.R121C, 
p.R336C, p.R369C and p.R491C. Until today, similar studies were implemented for CySH 
using other proteins than CBS, but with MEG only the p.R336C has been investigated 
(Mendes et al., 2015). To study whether the observed effects of incubation with CySH and 
MEG would not result in unwanted interactions with other Cys residues in CBS, we included 
in our work the CBS WT. We also extended our studies to the p.R491H variant as a negative 
control, to determine if the effect of the aminothiol compounds was specific for the variant 
Cys residue (Cys-specific). The rescue by aminothiols was assessed by monitoring not only 
CBS’s function, but also some of its biophysical properties, such as thermal stability and 
conformational flexibility. Finally, a method was developed to tentatively confirm MEG 
binding to the CBS variants. 
From the introduced changes, the p.R18C has been considered as a polymorphism 
(Lee et al, 2005), the p.R121C, p.R336 and p.R491C variants have been categorized as 
disease-causing, and the p.R164C has never been identified among the classical 
homocystinuric population. According to our data, the p.R18C, p.R369C, p.R491C and 
p.R491H variants presented enzymatic activities in the range or even higher than the WT 
protein and, except for p.R18C, all of the variants showed a proteolysis rate similar to the 
WT protein. Although the p.R18C had never been expressed in E. coli and characterized in 
vitro, it is important to highlight that this behavior has also been found for other CBS variants 
affecting the N-terminal CBS domain. In fact, when compared to the WT form, the p.P49L 
and p.P78R variants identified in CBS deficient patients present similar (p.P49L) or even 
higher (p.P78R) specific enzyme activities and proteolysis rate than the WT (Hnízda et al., 
2012). These observations corroborate previous data obtained by our group were a mild effect 
of amino acid changes occurring within the N-terminal domain were postulated (Mendes et 
al., 2014). 
Likewise, the variant proteins presenting amino acid changes in the C-terminal 
regulatory domain (p.R491C and p.R491H) presented specific enzyme activities higher than 
the WT. This is a known phenomenon resulting from a higher accessibility of the substrates 
to the catalytic domain upon conformational changes in the C-terminal domain inducing a 
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pre-activated structure. As shown in Figure 27, no major interactions will be disrupted by the 
substitution of Arg by a Cys. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27 – Structural representation of a CBS dimer with the R491 residue highlighted. In A, chain 
A is represented in pink and chain B is represented in blue with the corresponding C-terminal catalytic 
domains in dark pink and dark blue, respectively. In B the established interactions of the WT residue 
and the R>C and R>H substitutions are shown. Images were obtained using the crystal structure of a 
truncated form of CBS (PDB ID 4COO) and the UCSF Chimera, version 1.8.1. 
 
 
Concerning the p.R369C variant, contradictory data can be found in the literature. In 
fact, when studied in crude extracts of E. coli lysates, this variant presents only 15% of the 
WT activity and low expression (Kozich et al., 2010). However, when studied in CHO cells, 
the p.R369C presented ≈70% of residual activity, leading the authors to state that the net 
effect of the p.R369C substitution on quaternary structure and activity appears to be moderate 
in mammalian cells (Janošík et al., 2009), and that from the clinical standpoint may represent 
a functionally neutral genetic variant. Taking into consideration the structure presented in 
Figure 28 and the ASA value of 21% (partial buried residue) calculated for this residue, no 
significant structural changes would be predicted. 
 
 
R491 
R491 
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Figure 28 - Structural representation of a CBS dimer with the R369 residue highlighted. In A, chain 
A is represented in pink and chain B is represented in blue with the corresponding C-terminal catalytic 
domains in dark pink and dark blue, respectively. In B the established interactions of the WT residue 
and the R>C substitutions are shown. Images were obtained using the crystal structure of a truncated 
form of CBS (PDB ID 4COO) and the UCSF Chimera, version 1.8.1. 
 
 
As shown in Figure 29, the substitution of an Arg by a Cys in residues 121 and 164 
will probably lead to dramatic changes in the interactions that those residues establish with 
Glu239, Thr87 and Glu110 (for Arg121) or Glu187 (for Arg164), which would explain the 
low expression  levels obtained for both p.R121C and p.R164C variants. 
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Figure 29 - Structural representation of the R121 (A) and R164 (B) residues. The interactions 
established by the WT residue and by the R>C substitutions are shown. Images were obtained using 
the crystal structure of a truncated form of CBS (PDB ID 4COO) and the UCSF Chimera, version 
1.8.1. 
 
 
Kožich and colleagues (Kožich et al., 2010) analyzed the role of solvent accessibility 
of various mutants as a determinant of their folding and activity. In general, buried mutations 
exhibited much more profound detrimental effects on enzyme folding and activity compared 
to solvent-accessible mutations (Kožich et al., 2010), showing that the topology of mutations 
predicts in part the behavior of variant CBS proteins, and that misfolding may be an important 
and frequent pathogenic mechanism in CBS deficiency. This states the importance of solvent 
accessibility of mutations rather than their location in enzyme domains in predicting the 
properties of mutant enzymes. The accessible surface area (ASA) describes the area over 
which contacts between protein and solvent occur. The extent to which an amino acid residue 
interacts with its environment, the solvent and the protein core, is naturally proportional to 
the degree to which it is exposed to these environment. As such, to study the rescuing effect 
of aminothiols compounds, residues with different ASA values were selected. 
Previous work of our group already showed that when compared to MEG, CySH has 
a much more attenuated effect over the p.R336C variant (Mendes et al., 2015). We now show 
that this effect is also observed for the other R>C variants included in this study. In fact, 
A B 
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CySH increased the proteolysis rate, not only of the majority of the R>C variants, but also of 
the WT protein. These data suggest that in the presence of this aminothiol compound, the 
proteins present a higher conformational flexibility and/or a more opened structure. Only the 
p.R18C (proposed high ASA value) and p.R121C (buried residue, ASA value of 6%) were 
less prone to proteolysis by trypsin.  As such, CySH does not present a universal Cys-rescuing 
effect.  
Concerning the aminothiol compound MEG, a non-universal Cys rescue effect was 
also found. In fact, in the presence of this compound only the p.R18C, p.R121C and p.R336C 
variants decreased their proteolysis rate, which is translated into a higher catalytic activity. 
Again, the ASA values of these residues are quite different, since they range from highly 
exposed (p.R18C), to partially exposed (p.R336C; ASA 21%) and buried (p.R121C; ASA 
6%) residues. The DSF studies performed indicate that for the p.R336C variant a stabilization 
of the catalytic domain may explain the observed effect.   
Taken together, our data strongly suggest that the rescue of R>C variants by 
aminothiol compounds is not an universal effect, but it will rather depend on the affected 
residue, and as such, a case-by-case study should always be performed. 
 In order to monitor the number of available Cys residues accessible to thiol 
modification, a PEG-Mal assay was established. Although the obtained data did not allow to 
clearly show the expected changes in the MM, we postulate that further optimization of this 
technique will contribute to identify the presence of mixed thiols.  
 During this work, a CBS deficient patient was identified presenting the 
c.1013T>C mutation (p.L338P). As stated before, around 50% of CBS deficient patients 
respond to high doses of pyridoxine, thus being classified Vitamin B6-responsivess. 
Therefore, we embraced the expression and characterization of the p.L388P variant and, in 
particular, the enzyme response to the presence of PLP. The low expression levels of the 
produced variant precluded the complete biochemical and biophysical characterization, but 
suggest a strong effect on the protein folding, as would be expected by a change of a Leu to 
a Pro residue. The residue L338 lies at the core of the catalytic domain, at the end of helix12, 
and a change to a Pro probably will lead to a break in this secondary structure element. Work 
is on progress to increase the amount of expressed and purified variant in order to allow its 
thorough characterization. 
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